Atacama CEO on Excella deal and development of PDG for HPAPIs

By Gareth Macdonald

- Last updated on GMT

Related tags Pharmaceutical drug Pharmacology

Atacama CEO on Excella deal and development of PDG for HPAPIs
CEO Steffen Mittwich updates in-PharmaTechnologist on Atacama Labs' pneumatic dry granulation (PDG) API processing tech, its deal with German CMO Excella and future development plans.

PDG, as Mittwich explained, is a granulation technology that uses lower compaction forces than standard methods and a special classifying unit to produce active pharmaceutical ingredient (API) particles that have improved “flow-ability” and maximum binding capacity.

He went on to say that the firm plans to develop versions of the PDG machine for the processing of high-potency APIs for the production of oncology drugs and others that require specialised handling procedures like antibiotics.

Mittwich also said that, while Atacama is happy to be working with 10 ten global contract manufacturing organisation (CMO) Excella​, the firm is to expanding worldwide accessibility to PDG through future deals.

Related news

Related products

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Understanding the hidden value of quality

Understanding the hidden value of quality

Content provided by Thermo Fisher Scientific – Production Chemicals and Services | 16-Jan-2023 | White Paper

The raw material supply is too vital to leave to chance, and quality-related supply chain activities are cornerstones to your success.

Follow us

Products

View more

Webinars